Sponsor
Ariad Pharmaceuticals
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Ariad Pharmaceuticals appears in 9 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownA Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibNCT03535740 · lead sponsor · 2019-01-31
COMPLETEDALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsNCT02737501 · lead sponsor · 2016-05-26
COMPLETEDA Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNCT02094573 · lead sponsor · 2014-06-04
COMPLETEDA Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)NCT01449461 · lead sponsor · 2011-09-20
COMPLETEDAn Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNCT02784158 · lead sponsor
NO_LONGER_AVAILABLEStudy of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · collaborator · 2013-09-24
COMPLETEDA Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)NCT00818675 · collaborator · 2009-03-01
TERMINATEDBicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)NCT00777959 · collaborator · 2008-10-01
COMPLETEDRidaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)NCT00110188 · collaborator · 2005-05-01
COMPLETEDSponsor roles
lead sponsor5
collaborator4
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.